Screener
ANI Pharmaceuticals ANIP Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| (in thousands) | June 30, 2026 / Gross Carrying Amount | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Net Carrying Amount | December 31, 2025 / Gross Carrying Amount | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Net Carrying Amount | Remaining Weighted Average Amortization Period (1) |
|---|---|---|---|---|---|---|---|
| Definite-Lived Intangible Assets: | |||||||
| Acquired ANDAs intangible assets | $214,417 | $(158,199) | $56,218 | $214,260 | $(147,511) | $66,749 | 3.3 years |
| NDAs and product rights | 679,804 | (294,946) | 384,858 | 673,554 | (271,818) | 401,736 | 9.8 years |
| Marketing and distribution rights | 17,157 | (16,676) | 481 | 17,157 | (16,195) | 962 | 0.5 years |
| Customer relationships | 24,900 | (16,600) | 8,300 | 24,900 | (14,821) | 10,079 | 2.3 years |
| Total Intangible Assets, net | $936,278 | $(486,421) | $449,857 | $929,871 | $(450,345) | $479,526 | 8.8 years |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- ANI Pharmaceuticals (ANIP) reported finite-lived intangible assets, accumulated amortization of $486.42M in Q2 2026.
- How has ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization changed year-over-year?
- ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization increased by 18.8% year-over-year, from $409.57M to $486.42M.
- What is the long-term trend for ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization has grown at a 20.7% compound annual growth rate (CAGR), from $255.86M to $450.35M.
- What does finite-lived intangible assets, accumulated amortization mean?
- Finite-Lived Intangible Assets, Accumulated Amortization
Ask your AI about ANI Pharmaceuticals's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude